Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia [1]

Annals of Hematology

Volumn 86, Issue 10, 2007, Pages 763-765

  Scholl, Sebastian ^a   Lüftner, Joachim ^b   Mügge, Lars Olof ^a   Schmidt, Volker ^a   Fricke, Hans Jürg ^a   Höffken, Klaus ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CASE REPORT; FEMALE; GENE MUTATION; GRANULOCYTIC SARCOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; REMISSION INDUCTION; SARCOMA, MYELOID; SKIN NEOPLASMS;

EID: 34548312125     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0323-5     Document Type: Letter

References (10)

1. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266
2. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739
3. Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM et al (2005) Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 106:3618-3620
4. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W et al (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106:3747-3754
5. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A et al (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106:3740-3746
6. Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R et al (2005) Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106:2854-2861
7. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY, Wu SJ et al (2006) Nucleophosmin mutations in de novo acute myeloid leukemia: The age-dependent incidences and the stability during disease evolution. Cancer Res 66:3310-3316
8. Rappaport H (1966) Tumors of the hematopoietic system: In: Atlas of tumor pathology, section 3, fascicle 8. Armed Forces Institute of Pathology, Washington, DC, pp 241-243
9. Swirski DM, Li YS, Matthews JG, Flemans RJ, Rees JK, Hayhoe FG (1984) 8;21 Translocation in acute granulocyte leukaemia: Cytological, cytochemical and clinical features. Br J Haematol 56:199-213
10. Bolli N, Galimberti S, Martelli MP, Tabarrini A, Roti G, Mecucci C et al (2006) Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol 7:350-352